COST-EFFECTIVENESS ANALYSIS OF TOCILIZUMAB VERSUS INFLIXIMAB FOR THE PATIENTS WITH RHEUMATOID ARTHRITIS IN KAZAKHSTAN

被引：1
|
作者：
Bektur, C. [1 ]
Kayir, F. [2 ]
Nurgozhin, T. [1 ]
机构：
[1] Nazarbayev Univ, Ctr Life Sci, Astana, Kazakhstan
[2] Nazarbayev Univ, Astana, Kazakhstan
来源：
VALUE IN HEALTH | 2014年 / 17卷 / 07期
关键词：
D O I：
10.1016/j.jval.2014.08.2607
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PMS37
引用
收藏
页码：A379 / A379
页数：1
相关论文
共 50 条
  • [31] COST-EFFECTIVENESS ANALYSIS OF TOCILIZUMAB SUBCUTANEOUS AS FIRST LINE BIOLOGIC MONOTHERAPY FOR RHEUMATOID ARTHRITIS MANAGEMENT IN GREECE
    Athanasakis, K.
    Tarantilis, F.
    Skroumpelos, A.
    Kyriopoulos, J.
    [J]. VALUE IN HEALTH, 2015, 18 (07) : A671 - A671
  • [32] COST-EFFECTIVENESS OF TOFACITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS IN CHINA
    Wang, B. C.
    Chen, Y.
    Furnback, W.
    Wu, Q.
    Dong, P.
    [J]. VALUE IN HEALTH, 2018, 21 : S197 - S197
  • [33] Cost-Effectiveness of Cardiovascular Screening in Patients With Rheumatoid Arthritis
    Kievit, Wietske
    Maurits, Jake S. F.
    Arts, Elke E.
    van Riel, Piet L. C. M.
    Fransen, Jaap
    Popa, Calin D.
    [J]. ARTHRITIS CARE & RESEARCH, 2017, 69 (02) : 175 - 182
  • [34] COST-EFFECTIVENESS ANALYSIS OF GOLIMUMAB FOR THE TREATMENT OF RHEUMATOID ARTHRITIS
    Desai, R. J.
    Rao, J.
    Biddle, A. K.
    [J]. VALUE IN HEALTH, 2012, 15 (04) : A39 - A39
  • [35] Cost-effectiveness analysis of rituximab for rheumatoid arthritis in Taiwan
    Lou, S. F.
    Chen, D. Y.
    Cheng, T. T.
    Huang, C. M.
    Lin, H. Y.
    Su, C. C.
    Tsai, W. C.
    Tseng, J. C.
    Wei, C. C.
    Yang, L.
    Hazard, S.
    Chang, D. M.
    [J]. VALUE IN HEALTH, 2008, 11 (03) : A257 - A258
  • [36] A cost-effectiveness analysis of biological treatments for rheumatoid arthritis
    Chiou, CF
    Wanke, L
    Yu, E
    Ofman, J
    [J]. VALUE IN HEALTH, 2004, 7 (03) : 223 - 223
  • [37] COMBINATION DMARDS FOR RHEUMATOID ARTHRITIS: A COST-EFFECTIVENESS ANALYSIS
    Tosh, Jonathan
    Wailoo, Allan
    [J]. RHEUMATOLOGY, 2009, 48 : I68 - I69
  • [38] OPTIMAL TIMING FOR TOCILIZUMAB ADMINISTRATION TO PATIENTS WITH RHEUMATOID ARTHRITIS IN JAPAN BASED ON A COST-EFFECTIVENESS ANALYSIS USING THE IORRA COHORT STUDY
    Tanaka, E.
    Inoue, E.
    Hoshi, D.
    Shidara, K.
    Sato, E.
    Inoue, Y.
    Seto, Y.
    Nakajima, A.
    Momohara, S.
    Taniguchi, A.
    Yamanaka, H.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 : 881 - 881
  • [39] Triple Therapy Versus Biologic Therapy for Active Rheumatoid Arthritis A Cost-Effectiveness Analysis
    Bansback, Nick
    Phibbs, Ciaran S.
    Sun, Huiying
    O'Dell, James R.
    Brophy, Mary
    Keystone, Edward C.
    Leatherman, Sarah
    Mikuls, Ted R.
    Anis, Aslam H.
    [J]. ANNALS OF INTERNAL MEDICINE, 2017, 167 (01) : 8 - +
  • [40] COST-EFFECTIVENESS OF TOCILIZUMAB FOR THE MANAGEMENT OF PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS DESPITE PREVIOUS DMARD THERAPY IN COSTA RICA
    Carlos, F.
    [J]. VALUE IN HEALTH, 2010, 13 (07) : A309 - A309
12345